Sun Pharma’s experimental drug SCD-044 did not meet its main goals in Phase 2 trials for psoriasis and atopic dermatitis. The ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15%, is indicated ...

Dharmik Patel, MD, is now seeing patients in Waconia for dermatology care. Dr. Patel treats a large range of conditions and ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 ...

Think of exosomes as a postal service for your skin. They carry things from A to B and allow your cells to communicate, just ...

The "Saudi Arabia Dermatological Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has ...

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

She was diagnosed with alopecia areata, an autoimmune condition that disrupts regular hair growth, at just 18 months old and ...

Scalp to shins relief with expert tips - Itching to know what’s causing that scratch? Learn how hydration, barrier repair, ...

Sun Pharma’s phase 2 trials of SCD-044 to treat moderate to severe psoriasis and atopic dermatitis fails to meet primary endpoint: Our Bureau, Mumbai Wednesday, June 4, 2025, 11 ...